Newron Pharmaceuticals (OTCMKTS: NWPHF) is one of 496 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare Newron Pharmaceuticals to related businesses based on the strength of its valuation, profitability, dividends, institutional ownership, risk, earnings and analyst recommendations.
This table compares Newron Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Newron Pharmaceuticals Competitors||-2,976.15%||-160.93%||-30.80%|
47.9% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 15.5% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a summary of current recommendations for Newron Pharmaceuticals and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Newron Pharmaceuticals Competitors||3077||9322||22344||662||2.58|
As a group, “Pharmaceutical preparations” companies have a potential upside of 37.06%. Given Newron Pharmaceuticals’ peers higher possible upside, analysts clearly believe Newron Pharmaceuticals has less favorable growth aspects than its peers.
Valuation & Earnings
This table compares Newron Pharmaceuticals and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Newron Pharmaceuticals||$15.17 million||N/A||-25.68|
|Newron Pharmaceuticals Competitors||$2.01 billion||$135.76 million||-3.49|
Newron Pharmaceuticals’ peers have higher revenue and earnings than Newron Pharmaceuticals. Newron Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Risk & Volatility
Newron Pharmaceuticals has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, Newron Pharmaceuticals’ peers have a beta of 1.10, indicating that their average share price is 10% more volatile than the S&P 500.
Newron Pharmaceuticals peers beat Newron Pharmaceuticals on 5 of the 9 factors compared.
Newron Pharmaceuticals Company Profile
Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system in Italy and internationally. The company offers Xadago (safinamide) for the treatment of Parkinson's disease. Its pipeline of products include Sarizotan for patients with Rett syndrome; Evenamide, a first add-on therapy for the treatment of patients with positive symptoms of schizophrenia; and Ralfinamide for patients with specific rare pain indications. Newron Pharmaceuticals S.p.A. has a collaboration agreement with Meiji Seika Pharma Co., Ltd. for the development and commercialization of safinamide in Japan and Asian territories. The company was founded in 1998 and is headquartered in Bresso, Italy.
Receive News & Ratings for Newron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Newron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.